Leukemia

Articles

Research investigating the highly selective, reversible BTK inhibitor pirtobrutinib found the drug was safe and active for treating patients with chronic lymphocytic leukemia as well as other B-cell malignancies.

Phase 1/2 Trial Demonstrates Activity of Pirtobrutinib in CLL, B-Cell Malignancies

The new combination treatment of ublituximab plus ibrutinib resulted in a higher overall response rate and a tolerable safety profile for patients with relapsed or refractory high-risk CLL.

Higher Overall Response Rates Observed When Adding Ublituximab to Ibrutinib Treatment for CLL

The GREEN trial analyzed treatment with obinutuzumab monotherapy or obinutuzumab plus chemotherapy for patients with previously untreated or relapsed/refractory chronic lymphocytic leukemia.

Tolerable Safety Profile, Positive Efficacy Found With Obinutuzumab Plus Chemotherapy for Patients With CLL

Data published in Patient Preference and Adherence found communication improved between patients with CLL and their oncologists when the risk of adverse events and patient goals were top of mind.

Prioritizing AEs May Lead to Improvement in Communication Between Patients With CLL and Their Oncologists 

When also considering age and Rai score, the effect of Charlson comorbidity index score on mortality was found to be statistically nonsignificant for patients with chronic lymphocytic leukemia, although higher scores were associated with worse overall and relative survival.

Study Suggests a High Charlson Comorbidity Index Score Negatively Impacts OS, RS in CLL

Overall, the phase 3 ELEVATE-RR trial demonstrated efficacy of acalabrutinib and a safety and tolerability profile that with was consistent with that observed in the broader acalabrutinib clinical development program.

Acalabrutinib Meets Primary End Point Versus Ibrutinib in Previously Treated, High-Risk CLL

Findings from a phase 1/2 trial indicate that lisocabtagene maraleucel plus ibrutinib may represent a viable treatment option for patients with heavily pretreated chronic lymphocytic leukemia or small lymphocytic lymphoma and high-risk disease features.

Promising Efficacy Data for Heavily Pretreated CLL/SLL Indicate Potential Benefit for Liso-cel Combination With Ibrutinib

A recent study revealed that by using standardized uptake value thresholds as determined by 2-[18F]-FDG PET/CT, investigators were able to predict the occurrence of Richter syndrome in patients with CLL.

Various Diagnostic Criteria by PET/CT May Assist in Predicting Richter Syndrome in CLL

Videos

An integrated analysis of 2 phase 3 studies with up to 6.5 years of follow-up reported the outcomes of first-line ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and high-risk genomic features.

Jan A. Burger, MD, PhD, on Long-Term Outcomes with Ibrutinib in High-Risk Patients with CLL/SLL

This pooled analysis from 4 clinical trials suggested that though patients with TP53 aberrations remain at risk for progression, first-line treatment with ibrutinib has meaningfully improved the poor prognosis in this high-risk population.

Chronic Lymphocytic Leukemia | Topics